泡泡玛特，逆市大涨！医药巨头，突传利好

Group 1 - The core point of the news is that Pop Mart's stock surged over 9% due to a share buyback and positive outlook from Morgan Stanley, while the overall Hong Kong market experienced a decline [1][5][6] - Pop Mart's share price increased by 9.07%, closing at HKD 197.20 per share, with a trading volume of HKD 58.79 billion, ranking fourth among Hang Seng Index constituents [5][6] - The company repurchased 1.4 million shares on January 19 at a total cost of HKD 251 million, with plans to cancel the repurchased shares [5][6] Group 2 - Morgan Stanley's report predicts Pop Mart's net profit for 2025 to be RMB 12.6 billion, with an expected cash reserve of RMB 20 billion by the end of 2025, indicating strong financial resources for shareholder returns [6] - Heng Rui Medicine announced the approval of clinical trials for its new drug HRS-2141, aimed at treating type 2 diabetes, marking a significant step in its drug development pipeline [7][10] - The drug HRS-2141 is a fixed-dose combination formulation, with no similar drugs approved in the domestic and international markets, and the company has invested approximately RMB 5.4 million in its development so far [10][11]